- RecruitingPHASE1, PHASE2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
This study is looking into a new drug, AZD3632, for certain blood cancers like leukaemia and myelodysplastic syndromes. It aims to check its safety, how well it works, and how the body handles it, both on its own and with another medicine.
For: Acute Lymphoblastic Leukaemia · Acute Myeloid Leukaemia · Higher-risk Myelodysplastic SyndromesUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
A Study of BGB-11417 in Participants With Myeloid Malignancies
This study is looking at a new drug, BGB-11417, for certain blood cancers like acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Researchers want to see if it's safe, what dose works best, and if it helps people, either alone or with another treatment called azacitidine.
For: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative NeoplasmUnited States · Australia · China